Publications by authors named "H-W Pfister"

Objective: To assess the impact of normothermic machine perfusion (NMP) on patients, medical teams, and costs by gathering global insights and exploring current limitations.

Background: NMP for ex situ liver graft perfusion is gaining increasing attention for its capability to extend graft preservation. It has the potential to transform liver transplantation (LT) from an urgent to a purely elective procedure, which could revolutionize LT logistics, reduce burden on patients and health care providers, and decrease costs.

View Article and Find Full Text PDF

Background: There are a variety of possible contraceptives available. While medical advice is an important resource for selecting the individual contraceptive, previous research has shown that the Internet has become an increasingly important source of health care information.

Objectives: This study aims to identify key trends in contraception-related web searches in Germany and thus allows conclusions about preferences and unmet needs with regard to pregnancy prevention.

View Article and Find Full Text PDF
Article Synopsis
  • Hepatocellular carcinoma (HCC) can be caused by factors such as non-alcoholic steatohepatitis (NASH), which is linked to an accumulation of inactive immune cells in the liver.
  • Immunotherapy targeting PD1 has been approved for HCC but doesn't effectively improve patient outcomes, particularly in those with NASH-HCC, as it may worsen the disease instead of helping.
  • Research suggests that CD8 T cells contribute to the development of NASH-HCC rather than supporting immune defense, indicating a need for better patient stratification based on the underlying causes of HCC.
View Article and Find Full Text PDF

Background: Activation of the RAS-RAF-MEK-ERK signaling pathway is thought to be the key driver of pediatric low-grade astrocytoma (PLGA) growth. Sorafenib is a multikinase inhibitor targeting BRAF, VEGFR, PDGFR, and c-kit. This multicenter phase II study was conducted to determine the response rate to sorafenib in patients with recurrent or progressive PLGA.

View Article and Find Full Text PDF